Use of antifungal agents in pediatric and adult high-risk areas

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 3, 2012, Pages 337-347

  Ramirez E ^a   Garcia Rodriguez J ^a   Borobia, A M ^a   Ortega, J M ^a   Lei, S ^a   Barrios Fernandez A ^a   Sanchez M ^a   Carcas, A J ^a   Herrero, A ^a   De La Puente, J M ^a   Frias J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; NYSTATIN; POSACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHILD; CRITICAL ILLNESS; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG UTILIZATION; FEMALE; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANT; INFECTION PREVENTION; INTENSIVE CARE UNIT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEWBORN; NONHUMAN; OBSERVATIONAL STUDY; PEDIATRICS; PREMATURITY; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC MYCOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; INAPPROPRIATE PRESCRIBING; INFANT; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; TRANSPLANTATION; YOUNG ADULT;

EID: 84857057481     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1315-x     Document Type: Article

References (58)

1. SE Vartivarian EJ Anaissie GP Bodey 1993 Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management Clin Infect Dis 17 Suppl. 2 S487 S491 8274615 10.1093/clinids/17.Supplement-2.S487
2. GS Martin DM Mannino S Eaton M Moss 2003 The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 1546 1554 12700374 10.1056/NEJMoa022139 (Pubitemid 36437931)
3. PA Pizzo 1993 Management of fever in patients with cancer and treatment-induced neutropenia N Engl J Med 328 1323 1332 8469254 1:STN:280:DyaK3s3is1SjtA%3D%3D 10.1056/NEJM199305063281808 (Pubitemid 23131375)
4. S Hadley AW Karchmer 1995 Fungal infections in solid organ transplant recipients Infect Dis Clin North Am 9 1045 1074 8747778 1:STN:280: DyaK28zlsVSrug%3D%3D (Pubitemid 26008614)
5. JR Wingard 1999 Fungal infections after bone marrow transplant Biol Blood Marrow Transplant 5 55 68 10371357 1:STN:280:DyaK1M3pslOltQ%3D%3D 10.1053/bbmt.1999.v5.pm10371357
6. EC Williamson MR Millar CG Steward JM Cornish AB Foot A Oakhill DH Pamphilon B Reeves EO Caul DW Warnock DI Marks 1999 Infections in adults undergoing unrelated donor bone marrow transplantation Br J Haematol 104 560 568 10086795 1:STN:280:DyaK1M7osVGquw%3D%3D 10.1046/j.1365-2141.1999.01229.x (Pubitemid 29119282)
7. L Saiman E Ludington M Pfaller S Rangel-Frausto RT Wiblin J Dawson HM Blumberg JE Patterson M Rinaldi JE Edwards RP Wenzel W Jarvis 2000 Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group Pediatr Infect Dis J 19 319 324 10783022 1:STN:280:DC%2BD3c3ktlWitA%3D%3D 10.1097/00006454-200004000-00011 (Pubitemid 30213071)
8. HM Blumberg WR Jarvis JM Soucie JE Edwards JE Patterson MA Pfaller MS Rangel-Frausto MG Rinaldi L Saiman RT Wiblin RP Wenzel National Epidemiology of Mycoses Survey (NEMIS) Study Group 2001 Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey Clin Infect Dis 33 177 186 11418877 1:STN:280:DC%2BD3MzlslGjtQ%3D%3D 10.1086/321811 (Pubitemid 32643332)
9. S Antinori M Nebuloni C Magni M Fasan F Adorni A Viola M Corbellino M Galli G Vago C Parravicini AL Ridolfo 2009 Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002 Am J Clin Pathol 132 2 221 227 19605816 10.1309/AJCPRAAE8LZ7DTNE
10. PH Chandrasekar G Alangaden E Manavathu 2000 Aspergillus: an increasing problem in tertiary care hospitals? Clin Infect Dis 30 984 985 10880326 1:STN:280:DC%2BD3cvisVOksg%3D%3D 10.1086/313832 (Pubitemid 32250356)
11. S Dixon E McKeen M Tabberer S Paisley 2004 Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature Pharmacoeconomics 22 7 421 433 15137881 10.2165/00019053-200422070-00002 (Pubitemid 38736877)
12. K de With M Steib-Bauert H Knoth F Dörje E Strehl U Rothe L Maier VW Kern 2005 Hospital use of systemic antifungal drugs BMC Clin Pharmacol 5 1 1 15703083 10.1186/1472-6904-5-1 (Pubitemid 41534963)
13. S Alonso A Arribi J Vergas MC Martín B Arce A Terleira A Portolés 2009 Estudio piloto de utilización de antifúngicos sistémicos en el Hospital Clínico San Carlos. Propuesta de un método de estúdio Rev Esp Quimioter 22 3 127 134 19662545 1:STN:280:DC%2BD1MrktFahtQ%3D%3D
14. Modified Karch-Lasagna algorithm. Spanish Pharmacovigilance System. In: Aguirre, C. Causalidad en Farmacovigilancia. In: Rodríguez, J.M., Aguirre, C. (Eds.) Pharmacovigilancia. Bibao: Servicio Editorial de la Universidad del País Vasco, pp 93-98
15. F Meunier C Lukan 2008 The First European Conference on Infections in Leukaemia-ECIL1: a current perspective Eur J Cancer 44 2112 2117 18707872 10.1016/j.ejca.2008.07.008
16. TJ Walsh EJ Anaissie DW Denning R Herbrecht DP Kontoyiannis KA Marr VA Morrison BH Segal WJ Steinbach DA Stevens J-A van Burik JR Wingard TF Patterson Infectious Diseases Society of America 2008 Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 327 360 18177225 1:CAS:528:DC%2BD1cXitlKqt7c%3D 10.1086/525258 (Pubitemid 351265310)
17. OA Cornely A Böhme D Buchheidt H Einsele WJ Heinz M Karthaus SW Krause W Krüger G Maschmeyer O Penack J Ritter M Ruhnke M Sandherr M Sieniawski JJ Vehreschild HH Wolf AJ Ullmann 2009 Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology Haematologica 94 1 113 122 19066334 10.3324/haematol.11665
18. JM Rowe N Ciobanu J Ascensao EA Stadtmauer RS Weiner DP Schenkein P McGlave HM Lazarus 1994 Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG) Ann Intern Med 120 2 143 158 8256974 1:STN:280:DyaK2c%2FnvFWkuw%3D%3D (Pubitemid 24027556)
19. PG Pappas CA Kauffman D Andes DK Benjamin Jr TF Calandra JE Edwards Jr SG Filler JF Fisher BJ Kullberg L Ostrosky-Zeichner AC Reboli JH Rex TJ Walsh JD Sobel Infectious Diseases Society of America 2009 Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious Diseases Society of America Clin Infect Dis 48 503 535 19191635 1:CAS:528: DC%2BD1MXjslantLY%3D 10.1086/596757
20. C León S Ruiz-Santana P Saavedra B Almirante J Nolla-Salas F Álvarez-Lerma J Garnacho-Montero MA León EPCAN Study Group 2006 A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization Crit Care Med 34 3 730 737 16505659 10.1097/01.CCM.0000202208.37364.7D
21. Protocolo de diagnóstico y tratamiento de infección fúngica invasora en pacientes críticos en UCI. Hospital Universitario 12 de Octubre. Madrid. Versión 1. Septiembre 2007
22. B Almirante D Rodríguez BJ Park M Cuenca-Estrella AM Planes M Almela J Mensa F Sanchez J Ayats M Gimenez P Saballs SK Fridkin J Morgan JL Rodriguez-Tudela DW Warnock A Pahissa and the Barcelona Candidemia Project Study Group 2005 Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003 J Clin Microbiol 43 1829 1835 15815004 10.1128/JCM.43.4.1829-1835.2005
23. RA Hajjeh AN Sofair LH Harrison GM Lyon BA Arthington-Skaggs SA Mirza M Phelan J Morgan W Lee-Yang MA Ciblak LE Benjamin LT Sanza S Huie SF Yeo ME Brandt DW Warnock 2004 Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program J Clin Microbiol 42 4 1519 1527 15070998 10.1128/JCM.42.4.1519-1527.2004 (Pubitemid 38500790)
24. O Gudlaugsson S Gillespie K Lee J Vande Berg J Hu S Messer L Herwaldt M Pfaller D Diekema 2003 Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 37 1172 1177 14557960 10.1086/378745 (Pubitemid 37372504)
25. DJ Diekema SA Messer AB Brueggemann SL Coffman GV Doern LA Herwaldt MA Pfaller 2002 Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study J Clin Microbiol 40 1298 1302 11923348 1:STN:280:DC%2BD383htVGisw%3D%3D 10.1128/JCM.40.4.1298-1302.2002 (Pubitemid 34279892)
26. D Abi-Said E Anaissie O Uzun I Raad H Pinzcowski S Vartivarian 1997 The epidemiology of hematogenous candidiasis caused by different Candida species Clin Infect Dis 24 1122 1128 9195068 1:STN:280:DyaK2szjvVGjug%3D%3D 10.1086/513663 (Pubitemid 127774267)
27. GJ Slotman KW Burchard 1987 Ketoconazole prevents Candida sepsis in critically ill surgical patients Arch Surg 122 2 147 151 3545141 1:STN:280:DyaL2s7islCisw%3D%3D 10.1001/archsurg.1987.01400140029002 (Pubitemid 17007175)
28. MH Nguyen JE Jr Peacock DC Tanner AJ Morris ML Nguyen DR Snydman MM Wagener VL Yu 1995 Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study Arch Intern Med 155 2429 2435 7503601 1:CAS:528:DyaK28XksFWhuw%3D%3D 10.1001/archinte.1995. 00430220087009
29. JL Vincent E Anaissie H Bruining W Demajo M el-Ebiary J Haber Y Hiramatsu G Nitenberg PO Nyström D Pittet T Rogers P Sandven G Sganga MD Schaller J Solomkin 1998 Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care Intensive Care Med 24 3 206 216 9565801 1:STN:280:DyaK1c3is12hsA%3D%3D 10.1007/s001340050552 (Pubitemid 28190811)
30. C Prieto Yerro L Laredo Velasco Á Rodríguez Bernardino E Vargas Castrillón MI Ambit Ávila A Merchante Medina 2001 Modificación en el patrón de uso de anfotericina B no convencional tras la puesta en marcha de una intervención formativa en el Hospital Clínico San Carlos de Madrid Rev Esp Salud Pública 75 353 360 11693073 1:STN:280:DC%2BD3MnjslKgtA%3D%3D 10.1590/S1135-57272001000400009 (Pubitemid 32947612)
31. JH Powers CA Dixon MJ Goldberger 2002 Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever N Engl J Med 346 289 290 11807157 10.1056/NEJM200201243460414 (Pubitemid 34438872)
32. KW Garey MP Pai KJ Suda RS Turpin MD Rege DE Mingo DT Bearden 2007 Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines Pharmacoepidemiol Drug Saf 16 919 927 17286303 1:CAS:528:DC%2BD2sXhtVeitrzP 10.1002/pds.1365 (Pubitemid 47322590)
33. MH White 1997 The contribution of fluconazole to the changing epidemiology of invasive candidal infections Clin Infect Dis 24 1129 1130 9195069 1:STN:280:DyaK2szjvVGjuw%3D%3D 10.1086/513661
34. JJ Vehreschild A Böhme D Buchheidt D Arenz U Harnischmacher CP Heussel AJ Ullmann S Mousset M Hummel P Frommolt G Wassmer I Drzisga OA Cornely 2007 A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML) J Infect 55 445 449 17822770 10.1016/j.jinf.2007.07.003 (Pubitemid 47628350)
35. Playford EG, Webster AC, Sorrell TC, Craig JC (2004) Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev (3):CD004291
36. DJ Winston RW Busuttil 2002 Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients Transplantation 74 5 688 695 12352887 1:CAS:528:DC%2BD38XnsVarsLk%3D 10.1097/00007890-200209150-00017
37. CJ Cai SH Yi Y Guo MR Li HM Yi Y Yang MQ Lu GH Chen 2007 The impact of itraconazole versus fluconazole on the prevention of postoperative invasive fungal infections after orthotopic liver transplantation Zhonghua Nei Ke Za Zhi 46 11 911 913 18261273 1:CAS:528:DC%2BD1cXhsVSltbfF
38. EG Playford AC Webster TC Sorrell JC Craig 2006 Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients Eur J Clin Microbiol Infect Dis 25 9 549 561 16912905 1:CAS:528:DC%2BD28Xpt1Ontbk%3D 10.1007/s10096-006-0182-3 (Pubitemid 44379690)
39. JF Castroagudín C Pontón M Bustamante E Otero J Martínez S Tomé R Conde FR Segade M Delgado A Brage C Galbán E Varo 2005 Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients Transplant Proc 37 9 3965 3967 16386598 10.1016/j.transproceed.2005.10.043 (Pubitemid 43015225)
40. Clerihew L, McGuire W (2004) Systemic antifungal drugs for invasive fungal infection in preterm infants. Cochrane Database Syst Rev (1):CD003953
41. Austin NC, Darlow B (2004) Prophylactic oral antifungal agents to prevent systemic Candida infection in preterm infants. Cochrane Database Syst Rev (1):CD003478
42. P Manzoni R Arisio M Mostert M Leonessa D Farina MA Latino G Gomirato 2006 Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study Paediatrics 117 1 e22 e32 10.1542/peds.2004-2227 (Pubitemid 46050500)
43. KC Wade D Wu DA Kaufman RM Ward DK Benjamin Jr JE Sullivan N Ramey B Jayaraman K Hoppu PC Adamson MR Gastonguay JS Barrett National Institute of Child Health and Development Paediatric Pharmacology Research Unit Network 2008 Population pharmacokinetics of fluconazole in young infants Antimicrob Agents Chemother 52 11 4043 4049 18809946 1:CAS:528:DC%2BD1cXhtlCgs7jL 10.1128/AAC.00569-08
44. A Juster-Reicher E Leibovitz N Linder M Amitay O Flidel-Rimon S Even-Tov B Mogilner A Barzilai 2000 Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants Infection 28 223 226 10961528 1:CAS:528:DC%2BD3MXps1Cnug%3D%3D 10.1007/s150100070040 (Pubitemid 30601420)
45. BH Yang MY Peng SJ Hou JR Sun SY Lee JJ Lu 2009 Fluconazole-resistant Kodamaea ohmeri fungemia associated with cellulitis: case report and review of the literature Int J Infect Dis 13 6 e493 e497 19411182 1:CAS:528: DC%2BC3cXitVajsbc%3D 10.1016/j.ijid.2009.02.003
46. World Health Organization (WHO) (2003) Introduction to drug utilization research. WHO, Geneva
47. E Meyer F Schwab P Gastmeier H Ruden A Heininger 2007 Antifungal use in intensive care units J Antimicrob Chemother 60 3 619 624 17609195 1:CAS:528:DC%2BD2sXpt1CmtLk%3D 10.1093/jac/dkm255 (Pubitemid 47299878)
48. Cars O, Ekdahl K (2002) SWEDRES 2002. A report on Swedish antibiotic utilisation and resistance in human medicine. The Swedish Strategic Programme for the Rational Use of Antimicrobial Agents (STRAMA) and the Swedish Institute for Infectious Disease Control, Stockholm, pp 1-36
49. S Grau JM Torres-Rodríguez J Monterde 1996 Situación actual de las infecciones por hongos: ¿Son las anfotericinas lipídicas la panacea? Farm Hosp 20 390 392 (Pubitemid 27050636)
50. O Ericsson AC Hallmen I Wikstrom 1996 Amphotericin B is incompatible with lipid emulsions Ann Pharmacother 30 298 8833570 1:STN:280:DyaK28vjtVCntw%3D%3D
51. ER Kuse P Chetchotisakd CA da Cunha M Ruhnke C Barrios D Raghunadharao JS Sekhon A Freire V Ramasubramanian I Demeyer M Nucci A Leelarasamee F Jacobs J Decruyenaere D Pittet AJ Ullmann L Ostrosky-Zeichner O Lortholary S Koblinger H Diekmann-Berndt OA Cornely Micafungin Invasive Candidiasis Working Group 2007 Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 9572 1519 1527 17482982 1:CAS:528:DC%2BD2sXkvFGmt7c%3D 10.1016/S0140-6736(07)60605-9 (Pubitemid 46670281)
52. Rex JH, Lozano-Chiu M, Paetznik V and co-investigaors of the NIAID MSG Candidiasis Subproject (1998) Susceptibility testing of current Candida bloodstream isolates from Mycoses Study Group (MSG) Collaborative Study #34: isolates of C. krusei are often resistant to both fluconazole and amphotericin B [abstract 324]. In: Program and abstract of 36th Annual Meeting of Infectious Diseases Society of America (Denver): 136
53. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) 2008 EUCAST technical Note on fluconazole Clin Microbiol Infect 14 193 195 10.1111/j.1469-0691.2007.01899.x
54. M Nucci 2003 Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients Curr Opin Infect Dis 16 607 612 14624113 10.1097/00001432-200312000-00015
55. Voriconazole Spanish summary of product characteristics (available at: https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm& version=new, last accessed September 28, 2010)
56. FM Marty LA Cosimi LR Baden 2004 Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants N Engl J Med 350 950 952 14985500 1:CAS:528:DC%2BD2cXhsFyqsrw%3D 10.1056/NEJM200402263500923 (Pubitemid 38252550)
57. DI Zonios JE Bennett 2008 Update on azole antifungals Semin Respir Crit Care Med 29 2 198 210 18366001 10.1055/s-2008-1063858 (Pubitemid 351438997)
58. PP Cook PG Catrou JD Christie PD Young RE Polk 2004 Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram J Antimicrob Chemother 53 853 859 15044426 1:CAS:528: DC%2BD2cXjs1Wqtr4%3D 10.1093/jac/dkh163 (Pubitemid 38660291)